11-16 July 2022
Europe/Moscow timezone
For authors of online talks: we will send videoconference links 1 day before the session to e-mail addresses specified in the Registration form

NASOLACRIMAL DUCTS PHARMACOSAFETY OF 131-IODINE

15 Jul 2022, 16:00
20m
НИИЯФ, 19к, ауд. 2-15

НИИЯФ, 19к, ауд. 2-15

Ленинские Горы, д.1, стр. 5
Oral talk (15 min + 5 min questions) Nuclear technology and methods in medicine, radioecology.

Speaker

Alexey Trukhin (Endocrinology Research Centre)

Description

Secondary obliteration of the lacrimal duct obstruction (SALDO) is one of radioiodine therapy complications in differentiated thyroid cancer observed in 9% of cases [1]. Development of methods for the prevention of SALDO one of the urgent tasks facing radiology and ophthalmology [2]. We analyzed the frequency of 131-iodine uptake nasolacrimal ducts in 203 patients on 72 h. after 131-iodine administration. Patients were divided in two groups according type of preparation to the radioiodine therapy: 103 used classic levothyroxine withdrawal for 3 weeks, 100 used recombinant human thyroid stimulating hormone to increase TSH level. Image segmentation method was developed for static 131-iodine scintigraphy of head and neck. Additionally, we made an attempt to highlight several groups of risk to develop SALDO in patients undergoing 131-iodine therapy.

The speaker is a student or young scientist Yes
Section 8. Nuclear technology and methods in medicine, radioecology

Primary authors

Alexey Trukhin (Endocrinology Research Centre) Mr Vasiliy Yartsew (FSBI «RIED») Mr Danila Udakov (Endocrinology Research Centre)

Presentation Materials